| Document |
Document Title |
|
WO/2012/060431 |
A patch with stable transdermal absorbability, regardless of temperature changes during storage, in a crystallized formulation of clonidine is provided. This patch is characterized by including a backing, and a plaster layer integrally l...
|
|
WO/2012/061415 |
The present invention is directed to compounds of formula (I) and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which arc inhibitor of Syk kinase. The present invention is also directed to intermedi...
|
|
WO/2012/059543 |
The invention relates to the use of an oral solid dosage form for the prevention or treatment of diseases of modern civilization, such as, for example cardiovascular diseases, cancers, hypertension, diabetes, osteoporosis, chronic kidney...
|
|
WO/2012/061459 |
Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: W is CH2 or O; Q is Formula (II), Formula (III) or Formula (IV); and R1, R2, R3, R4, n, and G are defined herein. Also disclosed are methods of...
|
|
WO/2012/058993 |
A use of ambrisentan or pharmaceutically acceptable salts thereof for preparing medicines for preventing or alleviating cardiac function injury or secondary diseases thereof caused by hypoxia, said secondary diseases being selected from ...
|
|
WO/2012/060718 |
The present invention relates to use of trans fatty acid or a salt, ester or precursor thereof or trans fatty acid-enriched milk fat comprising milk fat enriched with trans fatty acid or a salt, ester or precursor thereof; or sialic acid...
|
|
WO/2012/060607 |
The present invention relates to: a composition for dissolving thrombi comprising a peptide comprising the Arg-Gly-Asp motif; a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same; and...
|
|
WO/2012/059820 |
Disclosed are temperature-sensitive hydrogels having a gelation temperature of above about 30° C. These hydrogels comprise diblock or triblock polymers of the type A-B. A-B-A or B-A-B wherein the A block comprises hydrophobic, biodegrad...
|
|
WO/2012/059869 |
Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, t...
|
|
WO/2012/059507 |
The invention relates to a compound of formula (I), wherein A1 to A4 and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2012/061169 |
The present invention relates to compounds of formula (IA), (IB) and (IC) and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these comp...
|
|
WO/2012/059549 |
The invention relates to novel 6-fluoro-1h-pyrazolo[4,3-b]pyridines, to methods for producing same, to the use thereof alone or in combination for treating and/or preventing illnesses, and to the use thereof to produce drugs for treating...
|
|
WO/2012/061289 |
A method of using biologies to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonist...
|
|
WO/2012/059548 |
The invention relates to novel benzyl-substituted carbamates, to methods for producing same, to the use thereof alone or in combination for treating and/or preventing illnesses, and to the use thereof to produce drugs for treating and/or...
|
|
WO/2012/059416 |
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions s...
|
|
WO/2012/059818 |
Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): (I) or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 a...
|
|
WO/2012/055971 |
The present invention relates to methods for the production of atheroprotective vesicles. The invention is based on the finding that endothelial cells wherein the activity of the transcription factor KLF2 is induced and/or enhanced surpr...
|
|
WO/2012/058598 |
The present invention provides methods and therapeutic agents for lowering serum or plasma serotonin levels in a patient in order to prevent or treat hyperlipidemia or atherosclerosis. In preferred embodiments, the patient is known to ha...
|
|
WO/2012/056478 |
The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation...
|
|
WO/2012/057103 |
The present invention provides a novel means of suppressing the generation of statin lactones. The pharmaceutical composition of the present invention is characterized by containing a compound having HMG-CoA reductase inhibiting activity...
|
|
WO/2012/056976 |
Provided is a novel compound capable of inhibiting cardiac adenylate cyclase. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof. (In the formula, R1, R2 and R3 independe...
|
|
WO/2012/057492 |
The present invention relates to a rapamycin formulation using recombinant high-density lipoprotein which includes a mutant of apolipoprotein. More particularly, the present invention relates to a rapamycin formulation which improves the...
|
|
WO/2012/058529 |
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
|
|
WO/2012/056205 |
The invention provides a peptide comprising or consisting of SEQ ID NO: 1 and variants thereof, particularly comprising of consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical composit...
|
|
WO/2012/056509 |
The present invention provides a novel means of suppressing the generation of statin lactones. The pharmaceutical composition of the present invention is characterized by containing a compound having HMG-CoA reductase inhibiting activity...
|
|
WO/2012/058585 |
Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.
|
|
WO/2012/054988 |
The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently -(optionally ...
|
|
WO/2012/056048 |
The use of a USP7 inhibitor as an anti-inflammatory agent in the treatment of acute or chronic inflammation is described. The USP7 inhibitor can be a gene knockdown tool, for example a siRNA molecule, an antibody, or a potent small molec...
|
|
WO/2012/057613 |
The present invention is concerned with treatment, prevention, or prevention of progression of myocardial infarction or adverse cardiac remodeling related conditions such as heart failure, aneurysm formation and remote myocardial fibrosi...
|
|
WO/2012/058132 |
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular dise...
|
|
WO/2012/052555 |
The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50 % of L- arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight...
|
|
WO/2012/053622 |
Provided are: a genetically modified non-human animal and a genetically modified cell, in each of which the expression level of ATP1B1 is altered; a method for evaluating a blood pressure regulator and a method for evaluating a condition...
|
|
WO/2012/052205 |
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions compris...
|
|
WO/2012/054367 |
The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, ...
|
|
WO/2012/054315 |
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically accepta...
|
|
WO/2012/054718 |
This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.
|
|
WO/2012/048522 |
A new fructosylated puerarin represented by Formula (I), a preparation method therefor and a use thereof in preparation of drugs for treating cardio-cerebrovascular diseases and/or tumor related diseases. R1 and R2 in Formula (I) are eac...
|
|
WO/2012/050611 |
The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer t...
|
|
WO/2012/050162 |
The present invention provides: a novel cellular life span extending agent, particularly an agent for extending the life span of an endothelial cell, which comprises an extract derived from a plant belonging to the genus Cinnamomum; and ...
|
|
WO/2012/050513 |
A method is provided for identifying an individual at risk of developing cardiovascular disease such as atherosclerosis and associated diseases, by determining the presence of specific bacterial groups or species in the individual's oral...
|
|
WO/2012/048446 |
Use of chemical ingredients in Cynomorium as phytoestrogen is provided by the present invention. Particularly, use of Cynomorium, extracts of Cynomorium, or at least one ingredient chosen from chrysophanol, emodin, catechin, (-)-epicatec...
|
|
WO/2012/050184 |
The purpose of the present invention is to provide a pharmaceutical composition which comprises a medicinal agent and a collagen and has good handleability and sustained release properties. The purpose is achieved by a sustained-release ...
|
|
WO/2012/049190 |
The present invention relates to compounds of the formula I wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their us...
|
|
WO/2012/051111 |
Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
|
|
WO/2012/050151 |
Provided is a compound or a pharmaceutically acceptable salt thereof represented by general formula (I) which has an excellent blood glucose-lowering effect and protective effect on β cells or the pancreas, and also provided is a pharma...
|
|
WO/2012/046062 |
The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated...
|
|
WO/2012/047629 |
A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techn...
|
|
WO/2012/045286 |
Provided is a recombinant plasmid pAdTrack-CMV-VEGF165-PolyA-promoter-Ang-1 and pAdTrack-CMV-VEGF165-IRES-Ang-1, collection codes CCTCC M 2010221 and CCTCC M 2010220 respectively. Also provided is a recombinant adenovirus produced when s...
|
|
WO/2012/048125 |
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, re...
|
|
WO/2012/047826 |
The present invention provides methods for treating a disease or condition by administering to a subject at a frequency of more than 24 hours between doses, compositions and formulations of compounds having formula (I), and pharmaceutica...
|
